Open main menu

Psychiatrienet β

Trazodone-tranylcypromine

Revision as of 10:12, 7 May 2009 by Alexandra (talk | contribs) (Created page with '{{ Drugswitch | from = trazodone | to = tranylcypromine | stop = * '''Before day 0:''' gradually reduce dosage of trazodone to a maximum of 150 mg/day, when this dosage is > 1...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Trazodone
Type Antidepressant
Group other
links
Medscape Trazodone
PubChem 5533
PubMed Trazodone
Kompas (Dutch) Trazodone
Wikipedia Trazodone
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from trazodone to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop trazodone
  • Before day 0: gradually reduce dosage of trazodone to a maximum of 150 mg/day, when this dosage is > 150 mg/day.
  • Day 1: reduce dosage of trazodone to 75 mg/day.
  • Day 8: stop administration of trazodone.
Eenrichtingbord.png Start tranylcypromine
  • Day 8-14: a wash-out period of one week is necessary.
  • Day 15: start administration of tranylcypromine in a dosage of 20 mg/day.
  • If necessary, increase dosage of tranylcypromine.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.